Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

[1]  Carlos L. Arteaga,et al.  Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer , 2021, Clinical Cancer Research.

[2]  R. Arya,et al.  Altered Actin Dynamics in Cell Migration of GNE Mutant Cells , 2021, Frontiers in Cell and Developmental Biology.

[3]  R. Bianco,et al.  A review of the use of Next Generation Sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. , 2020, Critical reviews in oncology/hematology.

[4]  Kangdong Liu,et al.  p21‐activated kinase 4 promotes the progression of esophageal squamous cell carcinoma by targeting LASP1 , 2020, Molecular carcinogenesis.

[5]  S. Rayala,et al.  Clinical Evaluation of P21 Activated Kinase 1 (PAK1) Activation in Gliomas and Its Effect on Cell Proliferation , 2020, Cancer investigation.

[6]  F. Du,et al.  Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer , 2020, JAMA network open.

[7]  Zhendan He,et al.  P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer , 2020, Theranostics.

[8]  M. Ringel,et al.  p21-activated kinases in thyroid cancer. , 2020, Endocrinology.

[9]  R. Bianco,et al.  c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve? , 2020, Cancers.

[10]  A. Bardia,et al.  Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future , 2020, The Lancet.

[11]  Xiangqian Guo,et al.  Systemic analysis of the expression and prognostic significance of PAKs in breast cancer. , 2020, Genomics.

[12]  E. Winer,et al.  The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer , 2019, bioRxiv.

[13]  Yan Guo,et al.  Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer , 2019, Nature Communications.

[14]  J. Chernoff,et al.  Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer , 2018, Nature Communications.

[15]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[16]  Zhi Wei,et al.  PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas , 2017, Nature.

[17]  Q. Liao,et al.  Overexpression of PAK1 Correlates with Aberrant Expression of EMT Markers and Poor Prognosis in Non-Small Cell Lung Cancer , 2017, Journal of Cancer.

[18]  S. Chandarlapaty,et al.  Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence , 2016, Oncogene.

[19]  D. Fabbro,et al.  Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor. , 2015, ACS medicinal chemistry letters.

[20]  I. Nabi,et al.  Actin Cytoskeleton Regulation of Epithelial Mesenchymal Transition in Metastatic Cancer Cells , 2015, PloS one.

[21]  G. Calin,et al.  Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer , 2015, Clinical Cancer Research.

[22]  R. Neve,et al.  PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition , 2014, Journal of Pathology.

[23]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[24]  J. Chernoff,et al.  PAK signalling during the development and progression of cancer , 2013, Nature Reviews Cancer.

[25]  Zhipeng Wang,et al.  p21-Activated Kinase 1 (PAK1) Can Promote ERK Activation in a Kinase-independent Manner* , 2013, The Journal of Biological Chemistry.

[26]  M. Varella‐Garcia,et al.  Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models , 2013, Front. Pharmacol..

[27]  Todd R. Golub,et al.  PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling , 2011, Oncogene.

[28]  A. Harris,et al.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[29]  D. Knighton,et al.  Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth , 2010, Proceedings of the National Academy of Sciences.

[30]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[31]  Anupama E. Gururaj,et al.  p21-activated kinases in cancer , 2006, Nature Reviews Cancer.

[32]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[33]  J. Parsons,et al.  PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation , 2003, The Journal of cell biology.

[34]  S. Weed,et al.  Focal Adhesion Kinase: a regulator of focal adhesion dynamics and cell movement , 2000, Oncogene.

[35]  M. Mandal,et al.  Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer Cells* , 2000, The Journal of Biological Chemistry.

[36]  L. Lim,et al.  A brain serine/threonine protein kinase activated by Cdc42 and Rac1 , 1994, Nature.

[37]  A. Minden,et al.  P21 activated kinase signaling in cancer. , 2019, Seminars in cancer biology.

[38]  D. Gomez,et al.  Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. , 2017, Cellular signalling.

[39]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.